Introduction
Bone marrow stromal cells (BMSCs) are pluripotent cells that can be isolated from adult marrow and that display both in vitro and in vivo the ability to give rise to different mesenchymal lineages. This cell population can be easily isolated from marrow and significantly expanded in vitro from relatively small samples. Altogether, the properties of BMSCs make them the ideal candidate for cell-based therapeutic strategies for a variety of disorders by both local and systemic applications. Some therapeutic applications of BMSCs are either already in use, or soon to be routinely implemented. Still much larger perspectives are linked to the design of appropriate strategies for cell delivery and stable cell transduction. 1, 2 Although longterm engraftment of BMSCs after local transplant is well established, its efficiency after systemic infusion is still questionable. 1, 2 Several reports have shown that human BMSCs engraft after systemic infusion in conditioned immunodeficient mice, but the percentage of engraftment has been mostly assessed by PCR analysis and it has never been quantitatively evaluated. 3, 4 It is conceivable that subcutaneous implantation not only avoids the loss due to the fact that BMSCs are not normally circulating cells unable to cross the endothelial wall, but also lets the cells create a local microenvironment that enhances their survival.
In this study, we developed a system that allows assessment of the transplantability and the real productive engraftment of human bone marrow cells in nonconditioned NOD/SCID mice simply measuring the biological response of the mouse after transplant of BMSCs infected in vitro with a replication defective retrovirus encoding the human erythropoietin gene.
Our results demonstrate that the same number of ex vivo expanded human BMSCs that do not produce any detectable effect when transplanted by systemic infusion, is capable of long-term engraftment and efficient expression of the foreign gene when locally transplanted in an artificial tridimensional scaffold, where they can readily create a favorable microenvironment.
Results

BMSCs retroviral infection
Human primary BMSCs were infected using a replication incompetent amphotropic bicistronic retrovirus encoding the eGFP gene linked by an IRES sequence to the NEOr gene ( Figure 1 ). After two rounds of infection, using 25 MOI, Ϸ90% of the human BMSCs analyzed by FACS were GFP-positive (data not shown). Infected cells selected with G418 became 99% GFP positive. For all the subsequent experiments, BMSCs were infected with the same bicistronic retrovirus encoding the human EPO gene instead of the eGFP gene and using the same number of MOI (Figure 1 ). EPO production was evaluated on supernatants from EPO-transduced BMSCs by ELISA (285 ± 35 units per 10 6 cells per 24 h).
Differentiation ability of EPO BMSCs
The ability of EPO transduced BMSCs to differentiate toward the adipogenic lineage was evaluated by an in vitro assay, in comparison with non-transduced BMSCs, as described in the Materials and methods section. Adipocytes were already evident after 4 weeks of stimulation as in control cultures (Figure 2a) . Cultures of selected EPO transduced BMSCs were implanted in vivo for an ectopic bone formation assay or tested for cartilage formation in vitro as described in the Materials and methods section. Bone formation, as well as cartilage formation, was evident in the histological specimens as in control cultures (Figure 2b, c) .
EPO production by differentiated cells was assessed on BMSCs stimulated for chondrogenesis. In this assay, in fact, the majority of BMSCs acquire the chondrocytic phenotype. A reliable assessment of EPO production is not possible in the osteogenic and adipogenic differentiation assay as a significant percentage of cells retain the BMSCs undifferentiated phenotype. The expression level of EPO by transduced cells after chondrogenic differentiation in vitro (153 ± 12 units per 10 6 cells per 24 h) was comparable to that observed in undifferentiated BMSCs (208 ± 25 units per 10 6 cells per 24 h).
BMSCs dose/biological response NOD/SCID mice were transplanted subcutaneously with 0.5, 1.5, 5.0 and 10.0 × 10 6 EPO-transduced BMSCs to establish the minimum number of cells able to elicit the maximal hematocrit increase. We observed a linear increase in the hematocrit level proportional to the number of transplanted cells, which was already significant (P Ͻ 0.05) with 0.5 × 10 6 (Figure 3 ). Since we did not find a significant difference between 5.0 and 10.0 × 10 6 BMSCs, 5.0 × 10 6 BMSCs were used in all the following experiments.
BMSCs transplant by different routes
We transplanted the same number of EPO transduced BMSCs in NOD/SCID mice by different routes. Three groups of mice were transplanted with EPO transduced BMSCs either intravenously, or subcutaneously or subcutaneously vehicled by a tridimensional scaffold ( Figure  4a ). As a control, a fourth group of mice was transplanted subcutaneously with mock-transduced BMSCs ( Figure  4a ).
Hematocrit levels never displayed any detectable increase in mice transplanted intravenously, as well as in control mice (Figure 4a ). Survival and tissue distribution of BMSCs were evaluated on a group of mice intravenously transplanted with GFP transduced BMSCs and killed 17 days after transplant. Liver, spleen, bone marrow, kidneys and lungs were analyzed. No GFP-positive cells were detected in any of these tissues (data not shown).
A significant increase (P Ͻ 0.05) in the hematocrit was observed when cells were locally transplanted ( Figure  4a ). Hematocrit rose rapidly, reaching the maximal observed level within 2 weeks after the subcutaneous transplant. When cells were delivered without any scaffold, the biological response declined slowly reaching the baseline within 5 weeks. No evidence of transplanted cells was detected at the implant site. A much longer lasting response was observed when cells were delivered with a tridimensional scaffold. The decrease of the response in this group of mice was slower, remaining significantly higher (P Ͻ 0.05) than the base line level for up to 14 weeks (Figure 4a ). Plasma EPO levels in transplanted mice were in agreement with hematocrit kinetics (Figure 4b ).
To assess the influence of the chemical composition of the scaffold, three different biomaterials were used to deliver cells in vivo: hydroxyapatite particles, cross-linked collagen sponge and hyaluronic acid sponge. No differences were observed in the elicited biological response with any of the biomaterials used ( Figure 5 ).
When EPO transduced BMSCs were transplanted with hydroxyapatite particles, as evidenced by histological analysis, bone was formed (Figure 6a ). In the implants where BMSCs were carried by a collagen sponge, we found only loose connective tissue formation (Figure 6b ). Finally, in the hyaluronic acid sponges, BMSCs organized a non-homogeneous connective tissue, with areas of extracellular matrix deposition and a cell network infiltrating the hyaluronic acid (Figure 6c) .
At 12-14 weeks from primary implants and after the normalization of the hematocrit levels, mice were killed and scaffolds surgically removed. We harvested EPOtransduced human BMSCs from the primary tridimensional implants. Cells were then expanded in vitro and the percentage of human cells was evaluated as Ϸ80% by FACS analysis staining with the FITC monoclonal antibody anti-human MHC type I W6-32. EPO-transduced BMSCs were selected and re-implanted in secondary recipients using the same amount and same route of delivery used for the primary recipients. We observed hematocrit kinetics comparable to those found in primary recipients ( Figure 7) . The in vitro production of human EPO was also assayed on transduced BMSCs before implantation and on cells recovered from primary tridimensional implants, either non-selected or selected with G418. The cells recovered from primary implants and selected with G418- 
Discussion
Allogeneic bone marrow transplant does not produce detectable engraftment of donor bone marrow stromal cells. [5] [6] [7] This may be due to the low number of stromal cells transplanted, to the inappropriate route of delivery or to the lack of 'space' due to the relative radioresistance of the host stroma.
Is systemic infusion of BMSCs effective or is a local delivery to a target organ required? Systemic infusion relies on cells reaching a niche that allows their shortand long-term engraftment; hematopoietic stem cells (HSC) that are intra-vascular engrafted when transplanted intravenously in conditioned mice. However, BMSCs only occasionally circulate and cells expanded ex vivo from bone marrow aspirates are selected for their ability to adhere to plastic. It is then likely that, when transplanted in the bloodstream, these cells are unable to find an adequate environment for their survival.
A number of previous studies has shown that in vitro expanded and retroviral infected BMSCs are transplantable after systemic infusion in conditioned mice. 4, 8, 9 However, in most, if not all cases, the engraftment was detected by PCR, and an evaluation of the percentage of survival was never provided. Furthermore, results obtained by systemic infusion of mouse BMSCs may be misleading, because it is a common experience that these cells are contaminated by a large number of macrophages that are easily transplanted in this way.
Host ablation by chemotherapy or irradiation, routinely used for HSC transplantation, is less than satisfactory as a means to enrich engraftment when transplanted BMSCs are used for gene or cell therapy, because the toxicity associated with these treatments preclude their use in patients with nonmalignant diseases. Several studies in mice have demonstrated that engraftment does not require an empty 'niche'. 10, 11 Instead it appears to represent a competitive process between endogenous and
Figure 6 Microphotographs of histological sections of retrieved implants. Three different biomaterials were used to deliver EPO transduced BMSCs in vivo: hydroxyapatite particles (a), cross-linked collagen sponge (b) and hyaluronic acid (c). Implants were harvested 12-14 weeks after the transplant, formalin-fixed and processed for histological analysis. (a) Bone formation on to bioceramic particles after in vivo delivery. Bone tissue (BT) and bone marrow (BM). (b) In vivo loose connective tissue (CT) formation by EPO-transduced BMSCs delivered by collagen sponge. (c) Connective tissue (CT) formation by EPO-transduced BMSCs delivered by hyaluronic acid sponge. Cell-network (CN) formed by BMSCs infiltrating the hyaluronic acid substrate (HY). Hematoxylin/eosin staining (magnification, ×250).
infused stem cells, a process that may be altered by infusion of very large cell grafts even in nonablated recipients. 10, 11 Clinically relevant engraftment of genetically modified BMSCs in the absence of myeloablation remains a highly desirable goal for a widespread application of stem cell-based gene transfer in humans. To test the engraftment ability of mesenchymal cells in non-conditioned animals, we transplanted mice with human BMSCs expanded in vitro and transduced with a retrovirus carrying the EPO gene. Different routes of transplant were used: intravenously, subcutaneously and as organoids. Intravenous injection never produced a detectable effect, while a transient (5 weeks) biological response was observed after subcutaneous injection A long-lasting response was obtained only by the use of organoids.
Using a range of 0.5-5.0 × 10 6 injected BMSCs, we observed a linear relationship between the number of cells and the biological response. We therefore used the maximal number of cells within the linear ratio, that allowed us to evaluate the percentage of cell survival in a 10-fold range. When 5.0 × 10 6 cells were injected intravenously, we observed a response (if any) significantly lower than that elicited by 0.5 × 10 6 cells transplanted subcutaneously. Assuming that 100% of the cells injected subcutaneously survive for at least 1 week, we can conclude that less than 10% of the cells delivered intravenously can survive and engraft. Moreover, we never detected GFP-positive cells in the analyzed tissues of the recipient mice. The increased hematocrit level induced by local delivery showed a peak at 2 weeks and sharply declined after 4 weeks reaching the baseline level within 5 weeks. Other than cell death, this effect may be due to a suppression of the endogenous production of EPO. 12 However, when cells were vehicled by a 3D scaffold, the increased level of hematocrit was maintained for a much longer period of time, up to 14 weeks. Cells recovered from the implants, after the hematocrit had returned to a normal level, were able to grow in vitro and to secrete EPO although at an efficiency of 50%. Furthermore, when selected to eliminate silenced cells and expanded to a number equal to the primary implant and transplanted into a secondary recipient, they induced a biological response comparable to that obtained in the primary recipient. Therefore, considering that 5 × 10 6 cells were transplanted and that at least half a million EPO-transduced BMSC are needed to obtain a significant hematocrit increase, with a gene silencing level of about 50%, we can conclude that 1 million cells partially silenced are necessary to induce a biological response. When the hematocrit returns to the normal level, at least 80% of the Gene Therapy implanted cells have to be dead. It should be noted that gene silencing is differentiation independent as shown by in vitro differentiation experiments. Interestingly a similar set of results has been reported recently by Bartholomew and coworkers. 13 These authors obtained higher values of hematocrit, injecting intramuscularly as few as one million transduced cells in mice. The difference in the hematocrit level can be attributed to a different efficiency of gene transduction and/or to the particularly favorable environment in which cells were delivered.
We conclude that the route of in vivo delivery of engineered BMSCs have profound effects on their survival and ability to express a foreign gene. Thus, the survival of transplanted cells is a function of the microenvironment, and not an intrinsic property of BMSCs. We cannot exclude a very low engraftment level of BMSCs delivered intravenously, but more than 90% of them vanish shortly after the transplant. Cells implanted subcutaneously survive for several weeks and their survival and engraftment are enhanced when a tridimensional scaffold is provided, perhaps mimicking a physiological niche for theses kinds of cells.
Genetically modified BMSCs in a tridimensional scaffold can be used as a delivery system for releasing therapeutic proteins into the bloodstream. This method avoids the difficulty of BMSCs homing in the bone marrow and presents the advantage of the retrievability of organoids, should adverse effects be experienced.
Materials and methods
BMSCs preparation, retroviral infection and selection
Cell preparation: The experimental protocol was approved by the institutional ethical committee. Bone marrow (BM) donors were fully informed on the procedure and gave their written consent. BMSCs from iliac crest BM aspirates of normal donors (n = 4; age range 6-32 years) were prepared as previously described. 14 Briefly, mononuclear cells (MNC) were counted with a nuclear stain (0.1% methyl violet in 0.1 M citric acid) and 2.0 to 5.0 × 10 6 MNC were plated in 100-mm dishes in Coon's modified Ham's F-12 medium supplemented with 10% fetal calf serum (FCS), 1 ng/ml of fibroblast growth factor 2 (FGF-2) and incubated at 37°C in 5% CO 2 . The medium was changed the first time after 3 days and then twice a week. When first confluence was achieved, cells were harvested, replated at 1 × 10 5 per dish and infected with the EPO retroviral supernatant the day after.
Plasmid construction: The complete coding sequence of the human EPO gene (kindly provided by Dr DT Scadden, Massachusetts General Hospital, Boston, MA, USA) was PCR amplified, cloned and sequenced into the pLXIN retroviral vector (Clontech Laboratories, Palo Alto, CA, USA) to generate the pLEPOIN vector. The retroviral vector encoding the enhanced GFP gene (pLEIN) was purchased from Clontech.
Retroviral production:
To generate the amphotropic producer cell lines, the GP+E-86 ecotropic packaging cell line 15 was transfected with 10 mg of pLXIN, pLEIN or pLEPOIN using a standard Ca-phosphate method. Two days after transfection the supernatant was collected, fil-tered through a 0.22-m filter and used to infect the GP+env AM-12 amphotropic packaging cell line 16 in presence of polybrene (Sigma, St Louis, MO, USA) 8 g/ml for 16 h. The amphotropic packaging cell line was then selected with G418 (Gibco BRL, Paisley, UK) at 1 mg/ml (active form) for 10 days. After G418 selection, individual clones were collected and their titer assessed infecting HELA cells with a serial dilution of the different viral stocks. The selected clones produced a retroviral titer of 5 × 10 5 Neo-r colony-forming units (CFU) per milliliter. The absence of replication-competent retrovirus was assessed by the absence of serially transmitted G418 resistance on HELA and NIH3T3 cells. 17 Infection protocol: Human BMSCs were incubated for 12 h at a density of 10 5 cell/10 cm plate with 5 ml of the packaging supernatant supplemented with 8 g/ml of polybrene (Sigma) and filtered through a 0.22-m filter. A second cycle of infection was repeated after 12 h. A constant multiplicity of infection of 50 was maintained in all the experiments. Infected cells (GFP and EPO transduced BMSCs) were selected using G418 at 1 mg/ml. All the experiments involving the use of recombinant retroviruses were done in a BL-2 environment.
EPO transduced BMSCs differentiation potential
To evaluate the adipogenic potential of EPO-transduced BMSCs, cells were stimulated in medium supplemented with FCS 10%, 1.0 × 10 Ϫ7 M dexamethasone, 1.0 × 10
Ϫ9
M insulin. The appearance of adipocytic colonies was observed by phase contrast microscopy. Chondrogenic potential was evaluated by culturing 2.5 × 10 5 EPO-transduced BMSCs as a pellet in a conical tube in serum-free medium with minor variations to the system developed by Johnstone et al. 18 After 2 weeks, BMSCs pellets were formalin-fixed and paraffin-embedded for histological analysis.
Osteogenic potential was assessed with an in vivo ectopic bone formation assay. Briefly, transduced BMSCs were subcutaneously implanted in the back of immunodeficient female mice (NOD/SCID 30-90 day old). Cells were delivered together with hydroxyapatite particles (150-250 m) (Fin-Ceramica Faenza, Italy). Implants were retrieved 8 weeks after surgery, formalin-fixed and paraffin-embedded for histological analysis.
In vivo transplants
Non-conditioned immunodeficient female mice (NOD/SCID 30-90 day old) were used for BMSCs transplants. Animals were cared for and treated according to institutional guidelines. Before treatment, mice were anesthetized by intramuscular injection of xylazine (20 g/ml) and ketamine (30 g/ml). Three routes of transplant were used: tail intravenous injection (n = 7), dorsal subcutaneous injection (n = 7) and dorsal subcutaneous transplant (n = 16) with a tridimensional scaffold. For transplant experiments with scaffolds (5 × 5 × 3 mm), three different biomaterials were used as vehicle for EPOtransduced BMSCs: collagen sponge (Coletica, Lyon, France) (n = 4); hydroxyapatite particles (150-250 m) (Fin-Ceramica Faenza) (n = 4); hyaluronic acid sponge (Hyaff-11, FAB, Italy) (n = 8). BMSCs transplants with hydroxyapatite particles were performed as described. 19 Non-transduced and mock-transduced BMSCs were used as a control (n = 10). Unless otherwise indicated, all experiments were performed using 5.0 × 10 6 BMSCs.
To assess the distribution of GFP-transduced BMSCs, intravenously transplanted mice were killed 17 days after transplant. Liver, spleen, bone marrow, kidneys and lungs were harvested and processed for cryosections. The presence of GFP-positive cells was assessed using rabbit polyclonal antibodies against GFP (Clontech).
For re-transplant experiments, primary recipient mice (n = 3) were killed 12-14 weeks after the implants and scaffolds harvested. One half of the primary implant was formalin-fixed and processed for histological analysis. The other half was minced with a scalpel and processed for cell culture. Fibroblastic cells derived from the fragments of the biomaterial were harvested, replated and selected with G418. At confluence, selected cells were counted and transplanted in secondary recipient mice (n = 9) as for the primary transplants.
The human origin of cells derived from the ex vivo cultured implant was assessed by direct immunofluorescence using a FACS flow cytometer with the FITC monoclonal antibody anti human MHC type I W6-32 (ATCC, Bethesda, MD, USA).
Hematocrit evaluation and EPO assay
Hematocrit was determined by centrifugation in Na heparinized capillary tubes of blood obtained from the orbital venous plexus under anesthesia. Blood was harvested at time 0, 7, 14, 21, 28, 35, 42 days after the implant and then every other week. Every hematocrit value was derived from the mean of two blood samples for each animal.
The quantitative determination of human erythropoietin in the supernatant of cultured cells or in plasma of transplanted mice was performed using an ELISA assay (Medac, Germany) according to the manufacturer's instructions.
Statistical procedures
Values for all experiments were expressed as the mean ± standard error to the mean (s.e.m.). Statistical analysis was performed using Student's t test and a P value Ͻ0.05 was considered significant.
